Previous research suggests that medical advances played a negligible role in the large decline in mortality rates during the first half of the twentieth century. This paper, in contrast, presents evidence that sulfa drugs-the first pharmaceuticals effective at treating infectious diseaseswere an important cause of U.S. mortality declines after their discovery in the 1930s. Using timeseries and difference-in-difference methods (with infectious diseases unaffected by sulfa drugs as a comparison group), we present evidence on the effects of sulfa drugs on mortality. We find that sulfa drugs led to a 25% decline in maternal mortality, a 13% decline in pneumonia and influenza mortality, and a 52% decline in scarlet fever mortality between 1937 and 1943. Sulfa drugs also widened racial disparities in mortality, suggesting that new medical technology diffuses more rapidly among whites than blacks and consistent with the hypothesis that innovation initially increases inequality across population subgroups.
Introduction
The U.S. experienced unprecedented declines in mortality during the 20 th century. The age-adjusted death rate declined by 74%, and life expectancy increased by 56%, or 30 years (Bernard Guyer, Mary A. Freedman, Donna M. Strobino and Edward J. Sondik 2000) . Seventy percent of the increase in longevity occurred during the first half of the century, driven by improvements in infectious-disease mortality, the leading cause of death at the time. What caused these rapid gains is the subject of great debate and has important policy implications for developing countries today where infectious disease mortality remains high. The prevailing view is that medical advances played a negligible role in the mortality decline between 1900 and 1950.
The gains, instead, are attributed to rising living standards, better nutrition, and public health measures that improved water supplies, sanitation systems, and household hygiene (Thomas McKeown 1976 , John B. McKinlay and Sonya M. McKinlay 1977 , Robert W. Fogel 1994 , Samuel Preston 1996 , Preston and Michael Haines 1991 , David Cutler and Grant Miller 2005 .
This view seems uncontroversial for the first thirty years of the 20 th century. There were few effective medicines or therapies available to combat infectious diseases before the mid1930s, so medical care is indeed unlikely to have played an important role during this period.
Starting in the mid-1930s, however, there were major medical advances that could have contributed to mortality declines. The effects of these early medical technologies have not received much attention in the literature, due perhaps to data limitations and methodological challenges. Historical epidemiologists, such as McKeown, R.G. Record, and R.D. Turner (1975) and McKinlay and McKinlay (1977) , have observed that a large share of 20 th -century declines in infectious disease mortality preceded the advent of medical treatments and concluded that the cause of the advances must be something other than modern medicine. This reasoning, however, 3 does not rule out a role for medical advances. Other researchers have hypothesized about the impact of medical innovation on mortality, but do not empirically test the hypothesis (e.g., Irvine Loudon 1987) . The absence of evidence on the effect of medical innovations is very different from evidence of no effect, but it may have led the consensus view to be too dismissive of the role that medical advances played in mortality declines in the 20 th century.
In this paper, we attempt to shed new light on this question by examining the introduction of sulfa drugs in the mid-1930s, an important event in the history of modern medicine. Sulfa drugs were the first medicine to effectively treat a range of potentially-fatal bacterial infections, including streptococcal (strep) infections (most notably scarlet fever, puerperal sepsis, and erysipelas), pneumonia, and meningitis. Pneumonia alone accounted for 8% of total deaths in 1936. The production and sales of sulfa drugs increased rapidly after their discovery, with 10 to 15 million people treated with sulfa drugs in 1941 alone (Annabel Hecht 1984) . The next major medical advance was not until the mid-1940s when penicillin and other antibiotics became available. Therefore, the period from the mid-1930s to mid-1940s provides a unique opportunity to examine the effect of a new medical technology on mortality.
Despite the historical and medical importance of sulfa drugs, there is little empirical evidence on their contribution to mortality decline. One exception is a study by Melissa A Thomasson and Jaret Treber (2008) , who find that hospitalization of childbirth in the U.S. did not have a statistically significant effect on maternal mortality until after sulfa drugs became widely available in 1937. The limited empirical attention given to sulfa drugs may be due in part to the lack of disaggregated data on their diffusion, which makes it more challenging to estimate their effect on mortality. We confront this challenge by using several independent empirical 4 methods to provide indirect evidence on the effect of sulfa drugs. Collectively, this evidence suggests that sulfa drugs were an important contributor to mortality improvements in the U.S.
The timing of the discovery of sulfa drugs in combination with evidence of their rapid diffusion during a short period-when no other major factors are known to have affected mortality trends-enables us to obtain an estimate of the impact of sulfa drugs on mortality.
First, we test for structural trend breaks in the mortality time series. We test both whether the timing of the trend break lines up with the introduction of sulfa drugs and whether the trend break is statistically significant. For diseases treated with sulfa drugs (maternal mortality, pneumonia/influenza, and scarlet fever), we find evidence of trend breaks in the mortality data in 1937, the first year of large-scale sulfa drug production. 1 We find no break during the relevant period for other infectious diseases that were not treatable with sulfa drugs (control diseases).
Second, we estimate the magnitude of the effect of sulfa drugs on mortality using a difference-in-differences regression approach that compares mortality differences between treated and control diseases before and after 1937. Our estimates are based on the identifying assumption that post-1937 mortality declines for treated diseases, beyond those that occurred for the control diseases, are due to sulfa drugs. The results suggest that sulfa drugs were responsible for a 25% decline in maternal mortality, a 13% decline in pneumonia/influenza mortality, and a 52% decline in scarlet fever mortality between the pre-1937 and post-1937 periods. These declines account for between 40% and 75% of total declines for these causes of death during this period.
Third, because sulfa drugs diffused first in cities, we can validate our interpretation of the post-1937 mortality declines as being caused by sulfa drugs by testing whether the declines are 1 As shorthand, we call maternal mortality a disease, but it is more precisely a cause of death. Loudon 1992) . Thus, the mortality reductions from sulfa drugs should be smaller for blacks than for whites. We indeed find greater mortality declines for whites than blacks for each of the treated diseases. This evidence suggests that new medical innovation is initially associated with larger health disparities across population sub-groups.
The rest of the paper is organized as follows. The next section presents a brief history of sulfa drugs. In Section 3, we describe the data. Section 4 presents our tests for structural breaks, and in Section 5 we estimate the magnitude of the effect of sulfa drugs on mortality. In section 6, we investigate racial differences in the effect of sulfa drugs. Finally, Section 7 concludes.
History of sulfa drugs
Sulfa drugs were the first effective antibacterial agents to be produced in a pharmaceutical laboratory. Before the first sulfa drug was synthesized in 1932, infectious disease research and treatment was dominated by immunotherapy, which involved the use of either animal serum containing antibodies to treat patients (passive immunization) or vaccines to produce antibodies in individuals to prevent the occurrence of disease (active immunization) (Loudon 2002) . While serum was not widely used due to cost and the high risk of serum-related 6 illness, several important vaccine discoveries were made in the late nineteenth century, including the rabies vaccine (1885) and the diphtheria antitoxin (1891).
In the late 1920s, German researchers began investigating the antibacterial potential of textile dyes (Loudon 1991) . In 1932, Gerhard Domagk, a German scientist working at the chemical and dye company I.B. Farben, discovered that a red dye compound, "Prontosil," was successful in treating mice injected with streptococci. Domagk's results, however, were not published until 1935.
2 That same year, the Pasteur Institute in France showed that the active ingredient in the dye compound was sulfonamide. The structure of sulfonamide had been documented in the doctoral dissertation of an Austrian chemist, Paul Gelmo, in 1908 and the patent on it had long expired. Therefore, the technology for making sulfonamide was available, and anyone could produce it. It was also relatively inexpensive to produce. As a result, production and clinical testing of sulfonamide began on a large-scale soon after its discovery.
The first major clinical trial of sulfa drugs occurred in 1936 at Queen Charlotte's Hospital in England, when Prontosil was given to 38 women with serious cases of puerperal fever, a complication from childbirth caused by streptococcal infection that was the leading cause of maternal mortality at the time. The results, published in the June 1936 issue of the Lancet, reported a mortality rate of 8% among treated patients versus 24% among the previous 38 untreated patients (Leonard Colebrook and Maeve Kenny 1936a , 1936-1950) . More than 5000 sulfa compounds were developed by the early 1940s, not all of which proved to be effective (David M. Keifer 2001).
Until 1938, sulfa drugs were available without a prescription, though physicians routinely prescribed them, and beginning in 1938, a prescription was required (Barron H. Lerner 1991).
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3 It should be noted that for many clinical trials, particularly those involving diseases with high fatality rates, concurrent controls were not used for ethical reasons (Lerner 1991; Loudon 2002) . In other cases where disease fatality rates were relatively low, definitive conclusions about the effect of sulfa drugs on mortality could not always be reached. Nonetheless, the successful results of repeated clinical testing were still viewed as compelling evidence of sulfa drugs' effectiveness. 4 New York Times, April 9, 1939; New York Times, August 8, 1941 , New York Times, July 19, 1942 New York Times, April 4, 1940. 5 In 1937, 100 people died from consuming an "Elixir of Sulfanilamide", an untested liquid sulfa preparation. This incident led to the passage of the 1938 Federal Food, Drug, and Cosmetic (FDC) Act that mandated safety testing of drugs before marketing and prohibited the sale of some non-narcotic drugs without a prescription, including sulfa drugs. Sulfapyridine, a sulfa compound, was the first important new drug to be reviewed by the FDC Act (Lesch 2007) .
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The rapid diffusion of sulfa drugs was aided by the fact that their price was low, about $35 to $100 (2008 dollars) per patient for a full course of the life-saving medicine.
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The fact that sulfa drugs were a sensation and became widely available quickly is very useful for analyzing their effects. These characteristics of sulfa drugs' diffusion allow us to look for sudden changes in outcomes (i.e., mortality) right after sulfa drugs were discovered and entered into mass production. This approach would be inappropriate for a medical technology with more gradual adoption, since one could not demarcate a before and after period as sharply.
The subsequent development of penicillin and other antibiotics have largely overshadowed the revolutionary effect of sulfa drugs on medical practice and research. However, the brief 10-year period covering the discovery and widespread use of sulfa drugs was considered 'epochal' at the time, and sulfa drugs are credited today with ushering in a 'therapeutic revolution' (Long and four causes of death that were shown to be highly responsive to sulfa drugs in clinical trials: maternal mortality, pneumonia, scarlet fever, and meningitis. In our analysis, we refer to these four causes of death as "treated" diseases. The most common cause of maternal mortality, responsible for roughly 40% of maternal deaths in the mid-1930s, was puerperal fever (puerperal sepsis), caused by streptococcus bacteria, which was responsive to sulfonamide; therefore, we use maternal mortality as a proxy for death from puerperal fever (Loudon 1988) . In 1939, influenza, which was not affected by sulfa drugs, was combined with pneumonia into a single category in the vital statistics volumes. In order to achieve a consistent data series, we use the combined pneumonia/flu category for all years. For the years when disaggregated data are available, pneumonia accounts for about 75% of total deaths in the combined category.
We selected two diseases to serve as a comparison group, or what we loosely refer to as "control" diseases. An ideal control disease would be an infectious disease that is similar to the infectious diseases treated with sulfa drugs, with the exception that it does not respond to any sulfa compound. Another criterion is that there is a consistent mortality data series available. The two diseases that met these criteria are tuberculosis and diphtheria. We also collected data on three chronic diseases: diabetes, heart disease, and cancer. While chronic diseases are clearly very different from the infectious diseases treated with sulfa drugs, they can provide some insight into whether there were other factors that affected mortality rates for all diseases during the period when sulfa drugs were introduced.
In addition to the state-level series, we look at national series. The city-level mortality data were collected by Thomasson and Treber (2008) . These data have two limitations for our purposes: (1) they cover only 1928 to 1940 and (2) they contain information on maternal mortality but not other causes of death. During the relevant period, maternal deaths were reported at the city level for each city with a population of at least 10,000 (in states that had entered the death registration system). We focus our analysis on larger cities with populations of at least 25,000 (as of 1930), of which there are 267. (Loudon 1988 , WHO et al. 2004 ). The MMR declined by roughly 60%
between the pre-sulfa and post-sulfa periods; similarly large declines also occurred in Western
Europe. The pneumonia/influenza and tuberculosis disease categories were responsible for the largest share of infectious disease deaths between 1920 and 1950, and accounted for approximately 22% of overall mortality. Deaths due to scarlet fever, meningitis, and diphtheria were much less common during this period. However, mortality for all of these infectious diseases dropped by 50% to 85% between the pre-and post-sulfa period. It should be noted that post-sulfa period used in our regression estimates. Note that the state means are not an exact match to the national data because the national data series are age-adjusted and the state averages are not population-weighted.
measure of maternal mortality and is a more precise measure of risk in that it represents the risk of death once a woman has become pregnant. As noted earlier, the national maternal mortality series are not age-standardized.
The effect of sulfa drugs on mortality in the U.S.: Times series evidence
We use indirect methods to measure the effect of sulfa drugs on mortality because disaggregated data on the diffusion of sulfa drugs are not available. Ideally, to estimate the impact of sulfa drugs on mortality, we could estimate the following equation:
The dependent variable is the natural log of the mortality rate in state i and year t. The reason for modeling the log of the mortality rate is that medical advances are hypothesized to have a proportional change on mortality rates: if the initial rate of mortality is high, there is more room for mortality decline, so a medical advance should lead to a larger drop in the level of mortality than if the initial rate is low. Using proportional changes also facilitates comparisons of mortality change across diseases that have different levels of mortality initially.
The ideal independent variable in model (4.1) would be a measure of sulfa drug availability (supply) that is uncorrelated with the demand for sulfa drugs. The hypothesis is that when sulfa drugs become more available, mortality falls (β 1 < 0). In practice, researchers might use state-year level data on sales volume or number of prescriptions issued as a proxy for sulfa drug availability, but it is worth keeping in mind that such a regression would suffer from endogeneity bias. For example, sales of sulfa drugs are likely to be higher in places with higher mortality risk from diseases treatable with the drugs. There is also a data limitation in our case:
there are no data on the availability of sulfa drugs disaggregated by state or other subgroup for the period examined.
Instead, we use two facts about sulfa drugs to arrive at empirical tests of their effects.
First, we use the fact that the timing of the sulfa drug discovery can be taken as exogenous and 13 that, because sulfa drugs could not be patented, diffusion was rapid: the first year of large-scale production and sales of sulfa drugs in the U.S. was 1937 (U.S. Tariff Commission, 1936 Commission, -1950 .
This allows us to use time series techniques to test whether the timing of mortality declines corresponds with sulfa drugs' introduction in 1937. Second, there is strong evidence from clinical trials that sulfa drugs were effective against some infectious diseases but not others.
Therefore, we are able to use infectious diseases that were impervious to sulfa compounds as a comparison group in our analysis.
Graphical evidence on trend breaks in the mortality time series
Figures 1 to 4 depict trends in overall mortality and in mortality for the treated infectious diseases, control infectious diseases, and chronic diseases. 12 (Treated diseases are those which sulfa drugs were effective against, and control diseases are those which sulfa drugs were ineffective against.) All graphs show mortality on a log scale. The vertical line at 1937 indicates the first year of large-scale production of sulfa drugs in the U.S. techniques than those we use for the rest of the diseases in this study and, for this reason, we do not pursue meningitis further in our analysis. Also worth noting is that the mortality rate from 12 Graphs are based on national-level age-adjusted death rates, using 1940 as the standard, except in the case of MMR, which is based on aggregated state-level data.
14 pneumonia/influenza is very noisy, particularly in the pre-sulfa-drug period, which will most likely result in noisier estimates in our subsequent analysis.
In contrast to the treated diseases, mortality trends for the control and chronic diseases (Figures 3 and 4) do not show any noteworthy changes around the time that sulfa drugs were introduced. Death rates for the control diseases are trending downward and chronic diseases trending upward, with no obvious breaks in the trend lines. When penicillin was introduced around 1945, there is a steepening of the tuberculosis and diphtheria curves; penicillin (but not sulfa drugs) was an effective treatment against these diseases.
The graphs also show that between 1935 and 1937, there is a slight increase in overall mortality as well as mortality from several specific causes of death considered here. The cause of this uptick is a puzzle in the demographic literature and one that we do not attempt to solve in this paper. Its timing is somewhat unfortunate for our purposes since we are interested in structural breaks in our mortality series around 1937; however, this uptick exists in the mortality series for both treated and control diseases (and, to a lesser extent, for chronic diseases). To ensure that our results are not driven by this anomaly, we also check the robustness of our results to the omission of these years in our estimation.
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Formal tests of trend breaks in mortality time series
The graphs provide suggestive evidence of an increase in mortality decline associated with the introduction of sulfa drugs in 1937. We next conduct a more formal test for structural breaks in the trend lines. The macroeconomics literature contains several methods for identifying structural breaks in time series data. We use a method that does not require a priori assumptions about the precise timing of the break. 14 As noted earlier, national data on sulfa drug production indicate that 1937 was the first year of large-scale production and sales, so our hypothesis is that if sulfa drugs affected mortality, the strongest trend break should be detected around 1937. To conduct the QLR test, one first needs to specify an interval over which to test for possible break dates. The interval must allow for a sufficient number of data points on each end in order to estimate the regression line before and after the break point. Equation (4.1) is then estimated for each possible break date, τ, in the specified test window. After each estimation, the hypothesis of a possible break in the mean and trend is tested by using the F-statistic that tests 14 Interrupted time series models are commonly used in the program evaluation literature. However, the conventional practice is to assume a particular date that the program would have an impact and to test for a discrete change in the intercept or slope of the regression line at that point using conventional F-tests.
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the null hypothesis that δ 0 = δ 1 = 0. 15 The largest of the resulting F-statistics is used to identify the best possible break point and to determine the significance of the break using Andrews critical values (Andrews 2003) .
The QLR test, however, is only valid in the case of stationary data series. Our mortality series are not stationary. 17 To achieve stationarity, we use the first difference of log mortality,
as the dependent variable and estimate the following equation:
This model allows for a break in both the level and slope of the first-differenced mortality series.
Therefore, it tests for structural change in the slope of the mortality series and allows for a change in the curvature of the mortality series. As a result of using first differences, however, we cannot detect a change in the level of mortality. In other words, if sulfa drugs caused a drop in the level of mortality in a particular year but no change in the slope, this test would not detect the change. Therefore, we may be missing one element of the effect of sulfa drugs on mortality, and our test of the effects of sulfa drugs is conservative. Also note that to account for serial correlation, we compute Newey-West standard errors and allow the error structure to be correlated up to two lags.
We conduct the QLR test using national-and state-level data. The range of dates over which we test for possible breaks is based on two considerations: (1) having an adequate number 15 This is often referred to as the Chow Test. The QLR test is, in essence, a sequential Chow Test, where the largest F-test from these sequential tests is used to identify a possible break point. 16 Andrews (2003) critical values account for the fact that many possible break points are being tested and, therefore, there are many chances to reject the null hypothesis of no structural change. The critical values depend on the number of parameters that are being allowed to break and the fraction of the total date range that is being examined for possible breaks points (Stock & Watson, 2003) . 17 Stationary series fluctuate around a fixed mean level over time, which makes it easier to detect a true break in the series. The graphs strongly suggest the data are not stationary, and if we test for stationarity using an Augmented Dickey-Fuller test, we find that the mortality series are not stationary but that the first-differenced series are.
of data points before (after) the earliest (latest) break point in the range and (2) 20 The four treated diseases account for about 12% of total mortality in the pre-period and were not the only diseases treated with sulfa drugs, so it is not surprising that we detect a possible break in total mortality when sulfa drugs became widely available. In spite of our relatively low statistical power to detect a break point due to our short data series, the break is statistically significant at the 5% level in the case of scarlet fever. The only comparison disease that has a possible trend break around 1937 is heart disease, though the break is not statistically significant. This slowdown in the increase in heart-disease mortality, which can be seen in Figure 4 , could be due to the fact that sulfa drugs reduced pneumonia, and one of the complications from pneumonia is heart-disease mortality.
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As a specification test, we conduct the QLR test using different test windows to see if our results are sensitive to the range of years selected for possible break points. We also test for 18 There is little guidance in the literature on how much of the sample to "trim" on each side to create an appropriate test window. A common approach is to trim 15% from both ends. However, in the case of small samples such as ours, that would leave only 3 data points on either side of the test window. In addition, there is no evidence that the QLR test requires symmetrical trimming. Andrews (1993) provides a calculation and critical values that enable one to obtain critical values for all possible test intervals (updated critical values are found in Andrews (2003) ). 19 In our model specification, we allow for only one break date. The QLR test can be easily adapted to allow for multiple breaks. However, the identification of multiple breaks requires a longer time series than is used here. Therefore, our test identifies the strongest possible break, but does not rule out the existence of other break points. 20 The later break date for pneumonia/influenza mortality likely reflects the availability of a new sulfa compound more effective in treating pneumonia, sulfapyridine, beginning in 1938. 21 This suggests that perhaps some of the diseases we study are not independent. We nevertheless treat them as such in all of the analyses in this paper, since it is extremely difficult to account for dependence without making strong functional form assumptions.
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trends breaks in the level (rather than the log) of mortality. These results are presented in appendix Table A1 . We find that the results are robust to the window starting in 1925 through 1930, to end dates through 1945, and to using levels rather than logs.
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We next conduct the same structural break test using state-level mortality data. Graphical analysis of state mortality trends (not presented) suggests wide variation in the timing and magnitude of mortality change when sulfa drugs were introduced. This is unsurprising, as we would expect certain states to adopt new medical technology earlier and more widely than other
states. The results of the QLR test for structural breaks in the state-level data series, presented in 22 The results are virtually the same when using mortality levels rather than log mortality, with two exceptions (that strengthen our findings): the break in the MMR achieves statistical significance when using levels, and the break date for pneumonia/flu changes from 1938 to 1937. In addition, when using levels, the estimated break date changes from 1937 to 1945 for pneumonia/flu when the test window is expanded to include 1945, the year that penicillin was introduced. 23 The test identifies a slightly larger percentage of states with possible breaks when using mortality levels rather than logs. More specifically, the test identifies possible breaks in 41% of states for maternal and scarlet fever mortality and 78% of states for pneumonia/flu mortality. 
Difference-in-differences estimates of the effect of sulfa drugs on mortality
Next, we use regression analysis to estimate the impact of sulfa drugs on mortality.
Regression analysis allows us, first, to more formally test whether the trend breaks are larger for the treatment diseases than for the control diseases and, second, to measure the magnitude of the effect of sulfa drugs on mortality.
Based on the trend-break results above, our starting point is the assumption that the 1937 trend break for treated diseases, relative to control diseases, represents the effect of the introduction of sulfa drugs. To account for the possibility that other factors may have affected mortality around 1937, we use a difference-in-difference approach, where we compare pre-and post-1937 levels and trends in the treated diseases to pre-and post-1937 levels and trends in a control disease, tuberculosis. Diphtheria is excluded because a substantial percentage of stateyear observations have zero mortality and therefore undefined log mortality.) We also exclude chronic diseases in further analyses since they are less comparable to the treated diseases.
The identifying assumption is that the trends in control and treated diseases are similar, and that sulfa drugs are the only factor differentially affecting the treated diseases in 1937. We use state-level mortality data to estimate the following equations: 25 We investigated whether any state-level factors can explain these observed differences in the adoption of sulfa drugs across states, where adoption was proxied by the level of mortality decline around 1937. Using our differencein-differences setup, we tested for an association between state characteristics-such as income per capita, high school graduation rates, number of doctors and hospitals per capita, and percent of the population in urban areasand mortality declines due to sulfa drugs. We found some suggestive evidence that adoption was more extensive in states with higher levels of education and urbanization, but our results were generally inconclusive (in most cases, not statistically significant and sensitive to specification choice We estimate the equations separately for each treated disease using state-level mortality data from 1925 to 1943. 26 The results are presented in Table 3 . Panel A presents the results of our main specification. The coefficients of interest are negative and significant in both models for all three treated diseases, suggesting that the introduction of sulfa drugs led to significant mortality declines. Panel B shows that these results are robust to the exclusion of 1935 to 1937, the years of the uptick in mortality. While the estimated coefficients in the MMR and scarlet fever models are virtually unchanged in this second specification, the coefficients in the pneumonia/flu model are reduced by roughly half. This is not surprising given that the data for this disease are noisier and we have a short panel, and thus point estimates are sensitive to excluding a few points. But in all cases the estimates are negative and statistically significant.
To assess the size of the effect of sulfa drugs on mortality, we use the coefficients from Panel A, column 1, corresponding to model (5.1), which allows for only a mean change in mortality, but is less demanding of our data. In the MMR model, the coefficient of -0.28 implies that sulfa drugs resulted in a 25% decrease in MMR in the post period, or 163 (.25*653) fewer maternal deaths per 100,000 births between 1925-36 and 1937-43 . This accounts for 56% of the 26 As noted previously, years after 1943 are excluded to avoid possible confounding of our estimates from the introduction of penicillin in [1945] [1946] . Note that one could estimate related models using the national-level rather than the state-level data. Using state data has the advantage that there are over forty separate "experiments" on the effect of sulfa drugs, so the statistical tests have more power.
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total decline in MMR during this time period, which fell by about 292 deaths per 100,000 births between the two periods (see Table 1 for summary statistics). The estimates also suggest that sulfa drugs were responsible for a 13% decline in pneumonia/flu mortality (a decrease of 15 deaths per 100,000 people) and 39% of total mortality decline in this disease category. (If one assumes the averted deaths in the combined pneumonia/influenza category were from pneumonia, then sulfa drugs caused a 17% decline in pneumonia mortality.) Finally, the scarlet fever results imply that sulfa drugs led to a 52% drop in scarlet fever mortality, which accounts for 76% of total mortality decline for this disease between the pre-1937 and post-1937 periods.
These estimates are quite consistent with clinical trial estimates from the time (G.M. Evans and Wilfrid F. Gaisford 1938, Colebrook and Kenny 1936a) .
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Using these estimated effect sizes, in combination with the summary statistics presented in Table 1 , we can calculate the contribution of sulfa drugs to the overall mortality decline from 1937 to 1943. We first convert the decline in MMR due to sulfa drugs to a decline in the number of maternal deaths per 100,000 individuals, which we estimate to be 24%. We know that mortality from maternal causes, pneumonia/influenza, and scarlet fever accounted for 1.1 %, 10.5%, and 0.2% (respectively) of total deaths in the pre-sulfa period. Therefore, we estimate that sulfa drugs', through their effect on the three treated diseases, were responsible for 2 % of overall mortality decline between 1925-36 and 1937-43 [(.24*.011 This contribution is relatively small, which is not too surprising given the small share of total deaths accounted for by maternal complications and scarlet fever; the three treated diseases in 27 In clinical trials, sulfa drugs reduced mortality from puerperal fever (responsible for roughly 40% of maternal deaths in the pre-sulfa period) by about 81%, which implies a 32% reduction in maternal mortality, and reduced mortality from pneumonia by 50 to 70%, which implies a 37 to 52% reduction in pneumonia/influenza given that pneumonia comprised about 74% of the pneumonia/influenza category in the pre-sulfa period. As expected, we find that the decline in the population, as measured by our regression coefficients, is smaller than in the trials. Only a portion of the population with the disease took sulfa drugs, and drugs are generally more efficacious in a controlled, clinical setting. We do not have estimates from scarlet fever clinical trials.
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our analysis account for 11.7% of mortality in the pre-period. Our estimates, however, do not attempt to capture the total impact of sulfa drugs on mortality because we cannot account for the effects of sulfa drugs on mortality declines after 1943 and because, due to data limitations, we cannot study the effect on other diseases (such as meningitis, erysipelas, and cerebrospinal fever) that sulfa drugs also treated. 28 It is also worth noting that sulfa drugs made a larger contribution to life expectancy gains during the period, since the diseases they treated struck people at a relatively young age. We restrict the urban data to cities with populations of at least 25,000 for two reasons.
First, our hypothesis of a higher rate of diffusion in urban areas is more likely to hold in larger cities. Second, vital statistics data were not collected in cities smaller than 25,000 people in 1931 and 1932. Recall that our city-level data series includes maternal mortality only, and only covers the period from 1928 to 1940. Figure 5 shows that the MMR was higher in cities than at the state level until 1938, after which point an urban advantage emerges. While the mortality curves for both cities and states become noticeably steeper around 1936-7, the graph suggests that this slope change occurs earlier in cities. Because the city-level series end in 1940, however, we cannot estimate the timing of possible trend breaks using the time series methods used above, which require a longer panel.
We can, however, estimate the regression models. We impose a break in 1937 and test whether this break is larger in cities, using pooled city-and state-level maternal mortality data.
We estimate the following two regressions: where the dependent variable is the natural log of the maternal mortality ratio for category c (city-or state-level observation) in state i in year t, Urban is an indicator variable for whether the observation is a city, Post-1937 is a dummy variable equal to zero in the period from 1928 to 1936 and equal to one in the period from 1937 to 1940, and Year t is a continuous year variable. Equation (5.3) includes State*Post-1937 fixed effects (denoted γ it) , and allows for differential time trends in urban areas. Equation (5.4) also includes State* Post-1937 fixed effects interacted with Year t . These equations are analogous to those used before, with the treated-disease dummy replaced with an urban dummy. The hypothesis is that the interactions with Urban and Post-1937 (the coefficients β 1 in Equation (5.3) and both β 1 and β 3 in Equation (5.4)) should be negative. Since the error terms will be correlated between state and city data (given that state is the aggregate of urban and rural), we cluster the standard errors by state. Table 4 presents the regression results. For both equations, β 1 is negative and significant, suggesting that cities experienced statistically significantly larger declines in maternal mortality after 1937 compared to rural areas. In addition, in the second model, the slope of the MMR curve after 1937 is more negative in urban areas (β 3 is negative and significant), suggesting that mortality started to decline faster in cities compared to rural areas after sulfa drugs were introduced. Panel B again shows that, although the magnitude of these effects changes when the 1935-1937 years are excluded, the substantive conclusions of the analysis do not.
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Racial differences in the effect of sulfa drugs
We next compare the effect of sulfa drugs for whites and blacks. A growing literature posits that new medical technologies may increase inequalities in health because they tend to favor, at least initially, the better off, those who are more able to access and implement health- Northridge, Jo C. Phelan and Michael L. Ganz 1998).
We test this hypothesis for the case of sulfa drugs. There are several reasons to believe that sulfa drugs may have diffused more rapidly within the white population, leading to steeper declines in mortality for whites than blacks after sulfa drugs' introduction in 1937. During this period, the vast majority of blacks lived in lower-income Southern states and in predominantly rural areas, often at far distances from hospitals and physicians. Hospital segregation policies and greater resources in white facilities further contributed to lower health care utilization among blacks (Almond et al., 2006) .
In the case of maternal mortality, the rate of home deliveries by untrained midwives was still high among black women (and very low among white women) living in the South during this period, which may have reduced black mothers' access to sulfa drugs during and after delivery (Loudon 1992 , Almond et al. 2006 ). Thomasson and Treber (2008) find that in U.S. cities, greater rates of hospital births were associated with significant and large declines in MMR for both races after the introduction of sulfa drugs in 1937, but that the effect of hospitals on 27 MMR in the post-sulfa period was greater for blacks than whites. This may reflect the relatively poorer hospital care received by black mothers in the pre-sulfa drug period. We test whether these patterns are statistically significant by testing for trend breaks in the time series for blacks and whites, using the same methodology employed in Section 4. As shown in Table 5 , the QLR test using national data identifies a statistically significant break in 1937 in maternal and scarlet fever mortality for whites only. The test also identifies a break in pneumonia/influenza mortality in 1937-8 for both races, but the break is not statistically significant. For the state analysis, only the 18 states with black populations greater than 5% of the total population are included; most of these states are in the South. 32 Recall that the time series methods require us to drop state-diseases with zero mortality in any year, which results in a reduced sample size for scarlet fever and diphtheria. Thus, the state-level trend break tests 30 In their balanced city panel, Thomasson and Treber (2008) find that greater hospitalization of births in the pre-1937 period lowered MMR for whites only, but the effect was larger in the post-1937 period. However, in their unbalanced panel, the mortality effects of hospital-based deliveries in the pre-sulfa drug period are insignificant for both blacks and whites. 31 The graphs in Figure 6 are based on national-level age-and race-adjusted death rates using 1940 as the standard, except in the case of MMR, which is based on aggregated state-level data. 32 These states are Alabama, Arkansas, Delaware, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, Missouri, New Jersey, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. 28 should be interpreted with some caution. That said, we find that the trend break in the treated diseases, except scarlet fever, occurs when sulfa drugs were introduced more often for whites than blacks, suggestive of more widespread diffusion of sulfa drugs among whites. 33 Next, we examine whether post-1937 declines in mortality from our treated diseases were larger in magnitude for whites compared to blacks. Using the same difference-in-differences regression approach outlined in Section 5, we estimate equations 5.1 and 5.2 separately for blacks and whites. Table 6 reports the results. These results suggest that sulfa drugs led to a 26% decline in MMR for whites versus a 12% decline for blacks. In the case of pneumonia/flu, our estimates suggest that sulfa drugs led to a 21% decline in mortality for whites and an 11% decline for blacks. For scarlet fever, we find that sulfa drugs had no statistically significant effect on scarlet fever mortality for blacks, but resulted in a 55% decline in scarlet fever mortality for whites.
To determine whether the differences in the coefficients for blacks and whites are statistically significantly, we pool the race data and estimate fully interacted versions of the models. The results are shown in Panel C of Table 6 and confirm that whites experienced significantly greater mortality reductions from sulfa drugs than blacks for all of the treated diseases (a positive interaction coefficient implies a smaller decline for blacks than whites given that the effects of Treated* Post-1937 and Treated*Year*Post-1937 are negative) . Appendix Table A3 shows that these results are robust to omitting 1935 to 1937 in our estimations. Thus, whites appear to have benefited more (in the short term) from the introduction of sulfa drugs, in line with previous results in the literature that suggest that innovation increases health gradients, at least initially. Sulfa drugs are a particularly interesting case because, unlike most life-saving 33 The percent of states with trend breaks in 1936 to 1938 are not comparable to the all-race results in Table 2 because the samples are different. For closer comparability to Table 2, Table 5 also shows the whites-only data for all states (again dropping cases with zero mortality).
29 innovations, they were inexpensive. (The full course of medicine cost less than $100 (2008 dollars), as discussed in section 2.) This suggests that factors other than income were the major barrier to accessing medical breakthroughs for low-SES groups like blacks.
Conclusion
Medicine is regarded as playing a relatively minor role in mortality decline through much of the 20 th century. While several scholars have made compelling arguments in support of this view (e.g., McKeown 1976 , Fogel 1994 , McKinlay and McKinlay 1977 , there have been few attempts to statistically test the effect of specific medical measures on mortality decline. This paper addresses this shortcoming in the literature by using several statistical methods to produce an estimate of the impact of sulfa drugs-the first major pharmaceutical innovation to treat disease in the 20 th century-on mortality in the U.S.
We use time series and difference-in-difference estimation methods-whereby we compare mortality patterns before and after sulfa drugs were introduced between treated and control diseases-to arrive at an estimate of the impact of sulfa drugs. Our results suggest that sulfa drugs caused significant mortality declines for the three causes of death included in our estimations: maternal mortality, influenza and pneumonia, and scarlet fever. The introduction of sulfa drugs resulted in a 25% drop in maternal mortality, a 13% drop in pneumonia and influenza mortality, and a 52% drop in scarlet fever mortality between 1925-36 and 1937-43 . In addition, sulfa drugs significantly increased the pace of mortality decline for these diseases. We also find that these reductions were larger in cities than in rural areas.
Our findings also suggest that sulfa drugs initially increased racial inequalities in maternal and pneumonia/flu mortality by causing a larger decline in mortality among whites than 30 blacks between the pre-and post-sulfa periods. These results suggest that sulfa drugs diffused more rapidly among whites, and more generally support the hypothesis that medical innovation results in greater inequality across groups, at least initially. This finding is especially striking given that sulfa drugs were an inexpensive life-saving drug. the scarlet fever model due to zero mortality from scarlet fever. * p < .10; ** p < .05; *** p < .01 and mortality data from 1920 to 1950. The national estimates are based on age and race-adjusted mortality data, except for MMR. The state-level race analysis is based on 18 states with black populations equal to at least 5% of the total population, except for scarlet fever and diphtheria, where states with zero mortality for any years before 1948 are dropped from the analysis; the resulting sample sizes are 13 for scarlet fever and 10 for diphtheria. The state-level analysis for whites-only is based on 46 states that entered the registration area before 1930, except for scarlet fever and diphtheria, which is based on 28 states and 39 states, respectively. The dependent variable is the log of mortality rate. Newey-West standard errors are computed, allowing for autocorrelation in the error term for up to two lags. The test statistic is the maximal F-statistic from a sequence of Chow tests for each possible break date in the test window. Critical values were obtained from Andrews (2003) . * p < .10; ** p < .05; *** p < .01 Treated diseases refer to maternal mortality, pneumonia/flu, and scarlet fever. Tuberculosis serves as the control disease. Estimates are based on 1925 to 1943 state-level mortality data. Only states with black populations greater than or equal to 5% of the total population in 1936 are included (18 states for MMR and pneumonia/flu models). In three states, MMR data by race are available four years later than pneumonia/flu and scarlet fever data by race, which results in a total of 8 fewer state/year/race observations in the MMR models for each race. In the scarlet fever models, six states are dropped from the analysis due to a large proportion of year/state observations with zero mortality for blacks. In Panels A and B, Model (1) includes the main effect of Treated, state*post fixed effects, a continuous year variable, and its interaction with Treated; Model (2) additionally includes state*post fixed effects and their interaction with the continuous year variable. In Panel C, Models (1) and (2) include the same variables as in the previous panels plus their interaction with Black. Robust standard errors, clustered by state, are in parentheses. * p < .10, ** p < .05, *** p < .01
